CO5200848A1 - Derivados de 3(5)-ureido-pirazol, proceso para su prepa- racion y su utilizacion como agentes antitumorales - Google Patents
Derivados de 3(5)-ureido-pirazol, proceso para su prepa- racion y su utilizacion como agentes antitumoralesInfo
- Publication number
- CO5200848A1 CO5200848A1 CO00059913A CO00059913A CO5200848A1 CO 5200848 A1 CO5200848 A1 CO 5200848A1 CO 00059913 A CO00059913 A CO 00059913A CO 00059913 A CO00059913 A CO 00059913A CO 5200848 A1 CO5200848 A1 CO 5200848A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- cycloalkyl
- amino
- aminoalkyl
- aryl
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
- -1 carboxy, amino Chemical group 0.000 abstract 7
- 125000004103 aminoalkyl group Chemical group 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 3
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 abstract 3
- 125000003282 alkyl amino group Chemical group 0.000 abstract 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 3
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 abstract 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 3
- 125000001769 aryl amino group Chemical group 0.000 abstract 3
- 125000005129 aryl carbonyl group Chemical group 0.000 abstract 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 abstract 3
- 125000005110 aryl thio group Chemical group 0.000 abstract 3
- 125000004104 aryloxy group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical group 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000005016 hydroxyalkynyl group Chemical group 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 2
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 abstract 2
- 125000004414 alkyl thio group Chemical group 0.000 abstract 2
- 125000005014 aminoalkynyl group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- XAEGRAIWWBXIRR-UHFFFAOYSA-N 1h-pyrazol-5-ylurea Chemical class NC(=O)NC=1C=CNN=1 XAEGRAIWWBXIRR-UHFFFAOYSA-N 0.000 abstract 1
- 125000005097 aminocarbonylalkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/372,833 US6387900B1 (en) | 1999-08-12 | 1999-08-12 | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5200848A1 true CO5200848A1 (es) | 2002-09-27 |
Family
ID=23469810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00059913A CO5200848A1 (es) | 1999-08-12 | 2000-08-10 | Derivados de 3(5)-ureido-pirazol, proceso para su prepa- racion y su utilizacion como agentes antitumorales |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6387900B1 (enExample) |
| EP (1) | EP1202734B1 (enExample) |
| JP (1) | JP2003507328A (enExample) |
| KR (1) | KR20020060158A (enExample) |
| CN (1) | CN1379668A (enExample) |
| AR (1) | AR035557A1 (enExample) |
| AT (1) | ATE361070T1 (enExample) |
| AU (1) | AU6747000A (enExample) |
| BR (1) | BR0013277A (enExample) |
| CA (1) | CA2380786A1 (enExample) |
| CO (1) | CO5200848A1 (enExample) |
| DE (1) | DE60034683T2 (enExample) |
| EA (1) | EA200200249A1 (enExample) |
| ES (1) | ES2284518T3 (enExample) |
| HK (1) | HK1049790A1 (enExample) |
| HU (1) | HUP0301857A2 (enExample) |
| IL (1) | IL147925A0 (enExample) |
| MX (1) | MXPA02001497A (enExample) |
| NO (1) | NO20020687L (enExample) |
| NZ (1) | NZ517238A (enExample) |
| PE (1) | PE20010482A1 (enExample) |
| PL (1) | PL354058A1 (enExample) |
| SK (1) | SK2082002A3 (enExample) |
| WO (1) | WO2001012188A1 (enExample) |
| ZA (1) | ZA200201118B (enExample) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070244120A1 (en) * | 2000-08-18 | 2007-10-18 | Jacques Dumas | Inhibition of raf kinase using substituted heterocyclic ureas |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| MXPA02006338A (es) | 1999-12-24 | 2002-12-13 | Aventis Pharma Ltd | Azaindoles. |
| DK1268472T3 (da) | 2000-02-07 | 2004-12-06 | Bristol Myers Squibb Co | 3-aminopyrazolinhibitorer af cyclinafhængige kinaser |
| JP2004507455A (ja) | 2000-04-25 | 2004-03-11 | ブリストル−マイヤーズ スクイブ カンパニー | サイクリン依存性キナーゼ阻害剤としての、５−チオ−、スルフィニル−およびスルホニルピラゾロ［３，４−ｂ］−ピリジンの用途 |
| HRP20030140A2 (en) * | 2000-08-31 | 2003-04-30 | Pfizer Prod Inc | Pyrazole derivatives and their use as protein kinase inhibitors |
| AU2002215053A1 (en) * | 2000-11-27 | 2002-06-24 | Pharmacia Italia S.P.A. | Phenylacetamido- pyrazole derivatives and their use as antitumor agents |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| ES2400070T3 (es) † | 2001-12-03 | 2013-04-05 | Bayer Healthcare Llc | Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos |
| US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| ES2425739T3 (es) | 2002-02-11 | 2013-10-17 | Bayer Healthcare Llc | Sorafenib-tosilato para el tratamiento de enfermedades caracterizadas por angiogénesis anormal |
| KR20030071029A (ko) * | 2002-02-27 | 2003-09-03 | 주식회사 팜제니아 | 항암제 및 방사선 치료 증진제로서 유용한 조성물 |
| US20030225089A1 (en) * | 2002-04-10 | 2003-12-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors |
| DE10221052A1 (de) * | 2002-05-10 | 2003-12-04 | Transmit Technologietransfer | Wirkstoffe zu Therapie, Diagnostik und Prophylaxe von Erkrankungen, bei denen abnorme Proteinstrukturen auftreten |
| AU2003227741A1 (en) * | 2002-05-17 | 2003-12-02 | Pharmacia Italia S.P.A. | Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| CA2493458A1 (en) | 2002-07-24 | 2004-01-29 | Ptc Therapeutics, Inc. | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
| US20060160856A1 (en) * | 2002-09-05 | 2006-07-20 | Dahl Bjarne H | Diarylurea derivatives and their use as chloride channel blockers |
| EP1551809A1 (en) | 2002-10-09 | 2005-07-13 | Pfizer Products Inc. | Pyrazole compounds for treatment of neurodegenerative disorders |
| UA81790C2 (uk) | 2002-12-19 | 2008-02-11 | Фармация Италия С.П.А. | Заміщені піролопіразольні похідні як інгібітори кінази |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| GB0305426D0 (en) * | 2003-03-08 | 2003-04-16 | Glaxo Group Ltd | Novel compounds |
| DE602004011340T2 (de) | 2003-05-20 | 2008-11-06 | Bayer Healthcare Llc | Diaryl-harnstoffe mit kinasehemmender wirkung |
| AU2004240772B2 (en) | 2003-05-22 | 2011-04-28 | Nerviano Medical Sciences S.R.L. | Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors |
| US7141568B2 (en) | 2003-07-09 | 2006-11-28 | Pfizer Italia S.R.L. | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| NZ544920A (en) | 2003-07-23 | 2009-11-27 | Bayer Healthcare Llc | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
| TW200526204A (en) | 2004-02-03 | 2005-08-16 | Pharmacia Italia Spa | 1h-thieno[2,3-c]pyrazole derivatives useful as kinase inhibitors |
| US7244757B2 (en) | 2004-04-01 | 2007-07-17 | Pfizer Inc | Pyrazole-amine compounds for the treatment of neurodegenerative disorders |
| EP1609789A1 (en) * | 2004-06-23 | 2005-12-28 | Eli Lilly And Company | Ureido-pyrazole derivatives and their use as kinase inhibitors |
| HRP20080608T3 (hr) * | 2004-08-12 | 2008-12-31 | Pfizer Inc. | Triazolopiridinilsulfanilni derivati kao inhibitori p38 map kinaze |
| HRP20150765T1 (hr) | 2004-12-30 | 2015-10-09 | Janssen Pharmaceutica N.V. | Amid derivati piperidin- i piperazin-1-karboksilne kiseline te povezani spojevi kao modulatori amid hidrolaze masnih kiselina (faah) za lijeäśenje tjeskobe, boli i drugih stanja |
| US20060183758A1 (en) * | 2005-02-17 | 2006-08-17 | Cb Research And Development, Inc. | Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans |
| US7429800B2 (en) * | 2005-06-30 | 2008-09-30 | Sabic Innovative Plastics Ip B.V. | Molding composition and method, and molded article |
| WO2007009898A1 (en) | 2005-07-19 | 2007-01-25 | Nerviano Medical Sciences S.R.L. | 1h-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors |
| AR059826A1 (es) * | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| JP2009535388A (ja) * | 2006-05-03 | 2009-10-01 | アストラゼネカ アクチボラグ | ピラゾール誘導体、及びそのｐｉ３ｋ阻害薬としての使用 |
| KR20090071662A (ko) * | 2006-10-21 | 2009-07-01 | 애보트 게엠베하 운트 콤파니 카게 | 헤테로사이클릭 화합물 및 글리코겐 신타제 키나제 3 억제제로서의 이의 용도 |
| CL2008000119A1 (es) | 2007-01-16 | 2008-05-16 | Wyeth Corp | Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia. |
| JP5675343B2 (ja) * | 2007-04-18 | 2015-02-25 | プロビオドルグ エージー | グルタミニルシクラーゼ阻害剤としての尿素誘導体 |
| AU2008263166A1 (en) * | 2007-05-25 | 2008-12-18 | Janssen Pharmaceutica N.V. | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| EP2163541A1 (en) * | 2008-09-12 | 2010-03-17 | Bayer Schering Pharma Aktiengesellschaft | Piperazine derivatives for binding and imaging amyloid plaques and their use |
| JP2012504645A (ja) * | 2008-10-01 | 2012-02-23 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 健康な細胞に対する電離放射線の影響を低下させる又は防止するための医薬組成物 |
| US8461159B2 (en) * | 2008-11-25 | 2013-06-11 | Jannsen Pharmaceutica BV | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| US8598356B2 (en) * | 2008-11-25 | 2013-12-03 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| WO2010132725A2 (en) | 2009-05-13 | 2010-11-18 | The University Of North Carolina At Chapel Hill | Cyclin dependent kinase inhibitors and methods of use |
| WO2010141817A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| WO2010141809A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase |
| WO2012054093A2 (en) | 2010-01-29 | 2012-04-26 | The Regents Of The University Of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
| WO2012003476A2 (en) * | 2010-07-02 | 2012-01-05 | Ventana Medical Systems, Inc. | Hapten conjugates for target detection |
| AR082498A1 (es) * | 2010-08-20 | 2012-12-12 | Gruenenthal Gmbh | Derivados ciclicos de carboxamida y urea sustituidos como ligandos del receptor de vainiloide |
| US9266855B2 (en) | 2010-09-27 | 2016-02-23 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| CA2818046A1 (en) | 2010-11-17 | 2012-05-24 | The University Of North Carolina At Chapel Hill | Protection of renal tissues from ischemia through inhibition of the proliferative kinases cdk4 and cdk6 |
| CN103298816A (zh) | 2010-12-17 | 2013-09-11 | 内尔维阿诺医学科学有限公司 | 作为激酶抑制剂的取代的吡唑并-喹唑啉衍生物 |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| SG10201913053QA (en) | 2011-05-13 | 2020-03-30 | Array Biopharma Inc | Pyrrolidinyl urea and pyrrolidinyl thiourea compounds as trka kinase inhibitors |
| AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
| RS55593B1 (sr) | 2012-11-13 | 2017-06-30 | Array Biopharma Inc | Jedinjenja biciklične uree, tiouree, guanidina i cijanoguanidina korisna za lečenje bola |
| US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078408A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078331A1 (en) * | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(arylalkyl)-n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| SMT201800169T1 (it) | 2012-11-13 | 2018-05-02 | Array Biopharma Inc | Composti di n-pirrolidinile, n'-pirazolile-urea, tiourea, guanidina e cianoguanidina come inibitore di chinasi trka |
| US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| US9809578B2 (en) | 2012-11-13 | 2017-11-07 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trkA kinase inhibitors |
| WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078372A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| CN107417691B (zh) | 2013-03-15 | 2020-06-26 | G1治疗公司 | 高效的抗赘生剂和抗增生剂 |
| US9464092B2 (en) | 2013-03-15 | 2016-10-11 | G1 Therapeutics, Inc. | Transient protection of normal cells during chemotherapy |
| WO2015161288A1 (en) | 2014-04-17 | 2015-10-22 | G1 Therapeutics, Inc. | Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents |
| EP3154959B1 (en) | 2014-05-15 | 2019-07-10 | Array Biopharma, Inc. | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor |
| WO2016040848A1 (en) | 2014-09-12 | 2016-03-17 | G1 Therapeutics, Inc. | Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors |
| EP3191098A4 (en) | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| WO2020252240A1 (en) * | 2019-06-14 | 2020-12-17 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| US10988479B1 (en) | 2020-06-15 | 2021-04-27 | G1 Therapeutics, Inc. | Morphic forms of trilaciclib and methods of manufacture thereof |
| TW202229268A (zh) * | 2020-12-22 | 2022-08-01 | 大陸商上海拓界生物醫藥科技有限公司 | Ｃｄｋ２抑制劑及其製備方法 |
| JP2024502474A (ja) | 2021-01-08 | 2024-01-19 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための、尿素を有するヘテロ二環式化合物または類似体およびその組成物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3646059A (en) * | 1969-05-05 | 1972-02-29 | Du Pont | Plant growth regulatory ureidopyrazoles |
| US3754887A (en) * | 1969-05-05 | 1973-08-28 | Du Pont | Ureidopyrazoles defoliants |
| EP0788358B1 (en) | 1994-11-10 | 2004-03-31 | Millennium Pharmaceuticals, Inc. | Use of pyrazole compounds for the treatment of glomerulonephritis, cancer, atherosclerosis or restenosis |
| DE69720051T2 (de) * | 1996-12-03 | 2003-09-04 | Banyu Pharmaceutical Co., Ltd. | Harnstoffderivate |
| WO1998052941A1 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
| MXPA00006233A (es) | 1997-12-22 | 2002-09-18 | Bayer Ag | Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas. |
-
1999
- 1999-08-12 US US09/372,833 patent/US6387900B1/en not_active Expired - Fee Related
-
2000
- 2000-08-03 PE PE2000000771A patent/PE20010482A1/es not_active Application Discontinuation
- 2000-08-10 AR ARP000104118A patent/AR035557A1/es unknown
- 2000-08-10 CO CO00059913A patent/CO5200848A1/es not_active Application Discontinuation
- 2000-08-11 HK HK03101874.6A patent/HK1049790A1/zh unknown
- 2000-08-11 ES ES00955241T patent/ES2284518T3/es not_active Expired - Lifetime
- 2000-08-11 KR KR1020027001815A patent/KR20020060158A/ko not_active Withdrawn
- 2000-08-11 DE DE60034683T patent/DE60034683T2/de not_active Expired - Fee Related
- 2000-08-11 CN CN00812736A patent/CN1379668A/zh active Pending
- 2000-08-11 PL PL00354058A patent/PL354058A1/xx not_active Application Discontinuation
- 2000-08-11 NZ NZ517238A patent/NZ517238A/en unknown
- 2000-08-11 CA CA002380786A patent/CA2380786A1/en not_active Abandoned
- 2000-08-11 AU AU67470/00A patent/AU6747000A/en not_active Abandoned
- 2000-08-11 WO PCT/US2000/017878 patent/WO2001012188A1/en not_active Ceased
- 2000-08-11 MX MXPA02001497A patent/MXPA02001497A/es active IP Right Grant
- 2000-08-11 EA EA200200249A patent/EA200200249A1/ru unknown
- 2000-08-11 AT AT00955241T patent/ATE361070T1/de not_active IP Right Cessation
- 2000-08-11 EP EP00955241A patent/EP1202734B1/en not_active Expired - Lifetime
- 2000-08-11 IL IL14792500A patent/IL147925A0/xx unknown
- 2000-08-11 SK SK208-2002A patent/SK2082002A3/sk unknown
- 2000-08-11 BR BR0013277-2A patent/BR0013277A/pt not_active Application Discontinuation
- 2000-08-11 HU HU0301857A patent/HUP0301857A2/hu unknown
- 2000-08-11 JP JP2001516534A patent/JP2003507328A/ja not_active Withdrawn
-
2002
- 2002-02-08 ZA ZA200201118A patent/ZA200201118B/en unknown
- 2002-02-11 NO NO20020687A patent/NO20020687L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| HK1049790A1 (zh) | 2003-05-30 |
| KR20020060158A (ko) | 2002-07-16 |
| ES2284518T3 (es) | 2007-11-16 |
| NO20020687L (no) | 2002-04-03 |
| ATE361070T1 (de) | 2007-05-15 |
| PE20010482A1 (es) | 2001-04-20 |
| PL354058A1 (en) | 2003-12-15 |
| CN1379668A (zh) | 2002-11-13 |
| AR035557A1 (es) | 2004-06-16 |
| BR0013277A (pt) | 2002-06-18 |
| US6387900B1 (en) | 2002-05-14 |
| AU6747000A (en) | 2001-03-13 |
| EA200200249A1 (ru) | 2002-08-29 |
| IL147925A0 (en) | 2002-08-14 |
| SK2082002A3 (en) | 2002-09-10 |
| DE60034683D1 (de) | 2007-06-14 |
| JP2003507328A (ja) | 2003-02-25 |
| EP1202734B1 (en) | 2007-05-02 |
| MXPA02001497A (es) | 2003-07-21 |
| EP1202734A1 (en) | 2002-05-08 |
| EP1202734A4 (en) | 2004-09-01 |
| CA2380786A1 (en) | 2001-02-22 |
| WO2001012188A1 (en) | 2001-02-22 |
| ZA200201118B (en) | 2003-05-28 |
| HUP0301857A2 (hu) | 2003-09-29 |
| DE60034683T2 (de) | 2008-01-17 |
| NZ517238A (en) | 2004-01-30 |
| NO20020687D0 (no) | 2002-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5200848A1 (es) | Derivados de 3(5)-ureido-pirazol, proceso para su prepa- racion y su utilizacion como agentes antitumorales | |
| CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
| AR049646A1 (es) | Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados | |
| AR068413A2 (es) | Derivados 8-amino, metodos de preparacion, composiciones farmaceuticas y su uso en terapia | |
| DK1585739T3 (da) | Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer | |
| CO5721006A2 (es) | Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa | |
| PA8490601A1 (es) | Derivados quinolin-2-ona sustituidos con heteroarilo utiles como agentes anticancerigenos. | |
| AR082826A2 (es) | Inhibidores heterociclicos de mek, composiciones farmaceuticas que los contienen, usos, y metodos de preparacion de los mismos | |
| AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
| CO5261616A1 (es) | Inhibidores no peptidicos de la union celular dependientes de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias | |
| DK1261602T3 (da) | Imidazol-2-carboxamidderivater som Raf-kinaseinhibitorer | |
| PE20050013A1 (es) | Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c | |
| DOP2006000063A (es) | Derivados de ciclopropanocarboxamida | |
| AR006906A1 (es) | Derivados de indazol sustituidos, composiciones farmaceuticas que los contienen, uso de los mismos e intermediarios de sintesis | |
| ES2213007T3 (es) | Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2. | |
| TW200734322A (en) | Indole derivatives exhibiting PGD2 receptor antagonism | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR036248A1 (es) | Derivados de 2h-piridazin-3-ona, composiciones farmaceuticas que los contienen y un proceso para la preparacion de dichos derivados y el uso de dichos derivados para la preparacion de una composicion farmaceutica | |
| AR009413A1 (es) | Un compuesto, el cual es un derivado de distamicina benzoheterociclico, su utilizacion, un procedimiento para producirlo y una composicionfarmaceutica que lo comprende | |
| NO20092372L (no) | Substituerte acetofenoner anvendelige som PDE4-inhibitorer | |
| AR065249A1 (es) | Derivados nitrogenados condensados de analogos de nucleosidos, composiciones farmaceuticas que los contienen y usos para tratar y/o prevenir infecciones virales. | |
| CO5601021A2 (es) | Derivados de quinazolinona, composiciones farmaceuticas que los contienen y su proceso de preparacion y su uso como antagonistas cb | |
| ES2038678T3 (es) | Procedimiento para la preparacion de n-(2-alquil-3-mercapto-glutaril)-alfamino-acidos. | |
| EA200600694A1 (ru) | Дисульфидные, сульфидные, сульфоксидные и сульфоновые производные циклических сахаров и их применение | |
| MY136824A (en) | Substituted benzoxazinones and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |